Evidence map›Paper›PMID 42907901›Full record

ArticleJournal of nanobiotechnology2026

Synergistic nanotheranostic platform for fluorescence/magnetic resonance bimodal imaging-guided near infrared photoimmuno-chemodynamic thermal targeting therapy.

Kohei Matsuoka, Mizuki Yamada, Ryu Okada, Mibuko Shimada, Mikina Yoshida, Rika Fukushima, Kanna Umeda, Ayano Ohashi, Chiemi Oka, Ayako Kato and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Kohei Matsuoka *Division of Host Defense Sciences, Dept. of Integrated Health Sciences, Graduate School of Medicine, Nagoya University, Nagoya, Japan.
Mizuki Yamada *Division of Host Defense Sciences, Dept. of Integrated Health Sciences, Graduate School of Medicine, Nagoya University, Nagoya, Japan.
Ryu OkadaGraduate School of Medicine, Nagoya University, Nagoya, Japan.
Mibuko ShimadaJSR corporation, Tokyo, Japan.
Mikina YoshidaDivision of Host Defense Sciences, Dept. of Integrated Health Sciences, Graduate School of Medicine, Nagoya University, Nagoya, Japan.
Rika FukushimaDivision of Host Defense Sciences, Dept. of Integrated Health Sciences, Graduate School of Medicine, Nagoya University, Nagoya, Japan.
Kanna UmedaDivision of Host Defense Sciences, Dept. of Integrated Health Sciences, Graduate School of Medicine, Nagoya University, Nagoya, Japan.
Ayano OhashiDivision of Host Defense Sciences, Dept. of Integrated Health Sciences, Graduate School of Medicine, Nagoya University, Nagoya, Japan.
Chiemi OkaGraduate School of Engineering, Nagoya University, Nagoya, 464-8603, Japan.
Ayako KatoInstitute for Advanced Research, Advanced Analytical and Diagnostic Imaging Center (AADIC) / Medical Engineering Unit (MEU), Nagoya University, B3 Unit Frontier, Nagoya, Japan.
Misae ShimizuInstitute for Advanced Research, Advanced Analytical and Diagnostic Imaging Center (AADIC) / Medical Engineering Unit (MEU), Nagoya University, B3 Unit Frontier, Nagoya, Japan.
Chiaki KoikeInstitute for Advanced Research, Advanced Analytical and Diagnostic Imaging Center (AADIC) / Medical Engineering Unit (MEU), Nagoya University, B3 Unit Frontier, Nagoya, Japan.
Akira ItoGraduate School of Engineering, Nagoya University, Nagoya, 464-8603, Japan.
Mitsuo SatoDivision of Host Defense Sciences, Dept. of Integrated Health Sciences, Graduate School of Medicine, Nagoya University, Nagoya, Japan.
Kazuhide SatoGraduate School of Medicine, Nagoya University, Nagoya, Japan. sato.kazuhide.k5@f.mail.nagoya-u.ac.jp.ORCID https://orcid.org/0000-0003-3025-088X

Funding

JSPS KAKEN 21K07217, 25K03451, and 25K22916JST-FOREST JPMJFR2017
6 · The paper itself

Abstract

Near-infrared (NIR) photoimmunotherapy (PIT) is a promising cancer treatment strategy involving antibody-photoabsorber conjugates. However, the imaging depth and photobleaching susceptibility of the IR700 fluorescence used for treatment monitoring are limited, and antigen heterogeneity within tumors compromises the efficacy of strictly antigen-restricted therapies. We developed a synergistic nanotheranostic platform that integrates NIR-PIT, photothermal therapy, and chemodynamic therapy (CDT) into a single MRI-visible agent (NIR-PICT

Indexed as

ImmunotherapyMagnetic Resonance ImagingPhototherapyTheranostic NanomedicineAnimalsAntibodies, MonoclonalCell Line, TumorFemaleHumansInfrared RaysMagnetic Iron Oxide NanoparticlesMiceMice, Inbred BALB CMice, NudeAntibodies, MonoclonalChemodynamic therapyMagnetic resonance imaging-visible agentNear-infraredPhotoimmunotherapyPhotothermal therapySynergistic nanotheranostic platform

Identifiers

PMID42907901
PMCPMC13685112

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.